Ruvidar Effective in the Treatment of Herpes
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus the standard of care treatments Acyclovir and Abreva in a preclinical animal model.
Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Ruvidar TM has demonstrated a higher efficacy in the treatment of Herpes Simplex Virus, Type 1 ('HSV-1") versus standard of care treatments Acyclovir (1%) and Abreva in a preclinical animal model.
Herpes Simplex Virus ('HSV'), known as herpes, is a very common infection that can cause painful blisters or ulcers on the skin of an individual. It primarily spreads by skin-to-skin contact, while it is treatable, it is not curable. 1
There are two main types of HSV: 1
Type 1 ('HSV-1") generally spreads by oral contact and causes infections in or around the mouth, vermilion, upper or lower lip region (oral herpes or cold sores). It can also cause genital herpes. A majority of adults are infected with HSV-1.
Type 2 ('HSV-2") spreads by sexual contact and causes herpes in the genital region of an individual.
An estimated 3.8 billion people under the age of 50 (64%) globally have HSV-1, the main cause of oral herpes. An estimated 520 million people aged 15 to 49 (13%) globally have HSV-2, the main cause of genital herpes. 1
The global HSV treatment market size was estimated at $USD 2.8 billion in 2024 and is expected to balloon to $USD 4.7 billion by 2033. 2
The market growth can be attributed to the growing concerns over HSV infection, including, oral and genital herpes. Moreover, the infection is highly contagious, spreading via saliva, vaginal secretion or semen and is acquired unknowingly. These factors highlight the increasing need for treatment throughout the projected period. 3
North America accounted for the largest market share of 37.1% in 2024, which can be attributed to higher consumption of branded herpes drugs, escalating healthcare expenditure, increasing launch of generics and favorable reimbursement policies. 2
The HSV-1 lifecycle begins upon contact with mucosal surfaces and it is in this niche, where the virus actively replicates inducing local lesion formation. The virus then enters local sensory nerve endings and migrates back to neuronal cell bodies in the peripheral nervous system. It is in this location where the virus enters into a latent, non-replicative stage until later reactivation. 4
Despite longstanding attempts at therapy and prevention, HSV remains among the most prevalent human infectious viral pathogens; therefore, it's imperative to keep HSV from replicating by implementing advanced vaccines and more effective drugs to combat and defeat this pervasive disease.
In the latest Theralase® research, Balb/C mice were infected with human HSV-1 virus on Day 0.
TM (1%).
Figure 2. Abreva treatment of HSV-1 infected cutaneous lesions
To view an enhanced version of this graphic, please visit:
Acyclovir (1%) Treatment
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/2786/245623_3.jpg ]
Figure 3. Acyclovir (1%) treatment of HSV-1 infected cutaneous lesions
Cannot view this image? Visit:
Ruvidar TM (1%) Treatment
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/2786/245623_4.jpg ]
Figure 4. Ruvidar TM (1%) treatment of HSV-1 infected cutaneous lesions
Cannot view this image? Visit:
The results support the safety and efficacy of topically applied non-light activated Ruvidar® for accelerated healing of cutaneous HSV-1 lesions in a mouse model.
Pavel Kaspler, Ph.D., research scientist, Theralase®, who conducted the preclinical study stated, " I am extremely impressed with the efficacy of the Ruvidar TM to successfully heal the HSV-1 lesions in an animal model versus common standard of care treatments, currently available, such as Abreva and Acyclovir. My next set of experiments will be to increase the number of daily applications of Abreva, Acyclovir and Ruvidar TM (from once daily to 5 times daily) and increase the dosage of Acyclovir and Ruvidar TM (1 to 5%) to see how this affects the healing time of HSV-1 lesions. It is my hope that my preclinical research leads to the development of a clinical treatment to aid the multitude of individuals suffering from cold sores.'
Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer, Theralase® stated, " Based on the chemical properties of Ruvidar TM, I am not surprised that it has had such a dramatic effect on the inactivation of HSV-1 lesions in this animal model. It is well established in the literature that the HSV-1 virus' glycoproteins (glycans - gB and gC) are negatively charged, as is the Heparan Sulphate ('HS') receptors on a cell's surface (preferred binding site of the virus on a cell). This provides a novel mechanism (based on controlled electrostatic repulsion) that addresses how viruses balance between optimized viral attachment to target cells and efficient egress of progeny virus. 5,6 On the other hand, Ruvidar TM is positively charged. 7 This allows Ruvidar TM the unique ability to be able to bind to and block the glycoproteins on HSV-1, preventing binding to host cells, as well as on the HS cell surface receptors preventing the efficient egress of progeny virus. This leads to an inability of the virus to replicate, allowing accelerated healing of cold sore lesions. '
Roger DuMoulin-White, B.Sc., P.Eng., Pro.Dir., President and Chief Executive Officer, Theralase® stated, " As always, I am in awe of the ability of Ruvidar TM to effectively destroy cancer cells, as well as efficiently inactivate bacteria and viruses. Based on the success of this latest preclinical research, Theralase®, pending funding in 2025, will commence formulation of Ruvidar TM into topical form, complete GLP toxicology and commence a Phase I/II adaptive clinical study to demonstrate the safety and efficacy of Ruvidar TM in the accelerated healing of cold sore lesions in humans. '
1 2 3 Herpes Simplex Virus Treatment Market Size, Share & Trends Analysis Report By Type (HSV-1, HSV-2), By Drug (Acyclovir, Valacyclovir, Famciclovir), By Vaccine (Simplirix, Others), By Route of Administration, By End-use, By Region, And Segment Forecasts, 2024 - 2030
Herpes Simplex Virus Treatment Market Size, Share & Trends Analysis Report By Type (HSV-1, HSV-2), By Drug (Acyclovir, Valacyclovir, Famciclovir), By Vaccine (Simplirix, Others), By Route of Administration, By End-use, By Region, And Segment Forecasts, 2024 - 2030
4 Roizman B, Knipe DM, Whitley R. Herpes Simplex Viruses. 6th ed. In: Knipe DM, Howley PM, editors. Fields Virology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. pp. 1823-1897.
5 Transforms of Cell Surface Glycoproteins Charge Influences Tumor Cell Metastasis via Atypically Inhibiting Epithelial-Mesenchymal Transition Including Matrix Metalloproteinases and Cell Junctions. Mingzhe Wang et al. Bioconjugate Chemistry. Vol. 34. Issue 8. July 2023
6 Olofsson S, Bally M, Trybala E, Bergström T. Structure and Role of O-Linked Glycans in Viral Envelope Proteins. Annu Rev Virol. 2023 Sep 29;10(1):283-304. doi: 10.1146/annurev-virology-111821-121007. Epub 2023 Jul 6. PMID: 37285578.
7
About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
Additional information is available at www.theralase.com and www.sedarplus.ca.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements:
This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.
Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
416.699.LASE (5273)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Omada Health IPO signals healthier market, avoids 'down-round' trend
The IPO market is starting to feel healthier. Omada Health, a 14-year-old company providing virtual care for chronic conditions like diabetes and hypertension between office visits, closed its first trading day on Friday at $23 a share, a 21% jump from the IPO price of $19. The IPO valued the company just above $1 billion (excluding employee options), a figure that's nearly identical to Omada's last private valuation of $1 billion set in its previous VC round. The debut is one of the first among recent IPOs that was not a so-called down-round. Many of the latest public listings, including Hinge, ServiceTitan, and Reddit, priced below their private market highs, though have faired well as public companies. For founder and CEO Sean Duffy, the successful public offering validates his decision to start a company that he believed the market desperately needed. In 2011, he dropped out of Harvard Medical School after realizing that chronic illness patients required more continuous support than the existing healthcare system delivered. Before the offering, he owned 4.1% of the company, according to Omada's offering document. Other significant shareholders included Revelation Partners (10.9%), US Venture Partners (9.9%), Andreessen Horowitz (9.6%), and FMR (9.3%). Duffy told TechCrunch that over his 14-year journey as a founder, he had many harrowing moments. "I didn't think our series A was going to come together because we were working on this commercial deal that didn't materialize, and that spooked one investor," he said. "As a young business, something tries to kill you every month," he continued. "And then as the business grows, it turns into like every quarter or six months, year, two years." One of the recent challenges for many digital health businesses is navigating the "collapse" of the market post-COVID boom. Omada steered through the turbulent times by seeking new, rising markets. It recently expanded its offerings to include diet management support for GLP-1 patients.
Yahoo
9 hours ago
- Yahoo
46 State Medical Associations Urge Senate to Reject Medicaid Cuts in H.R. 1
The House Budget Reconciliation bill will cause at least 7.8 million Medicaid enrollees to lose their health care coverage. SACRAMENTO, Calif., June 6, 2025 /PRNewswire/ -- Just days ahead of an expected Senate vote on H.R. 1, 46 state medical associations, as part of Physicians for Medicaid have sent a letter to the United States Senate urging them to reject the dangerous cuts to Medicaid proposed in H.R. 1 that will cause millions of patients to lose coverage and even more to lose access to care - children, pregnant women, seniors, veterans, the disabled and working families. Statewide hospital associations have also weighed in, as proposed cuts impact all providers, including physicians and hospitals. The bill, which includes $200 billion in cuts to the existing and longstanding provider taxes, would have a catastrophic effect on state budgets and the country's entire health care delivery system and would impact 49 state Medicaid programs. Provider taxes have been authorized under federal law, approved by both Republican and Democratic administrations, and affirmed by state legislatures in 49 states for decades. They are a legitimate financing mechanism used by states in partnership with the federal government to fund essential health services and have kept rural hospitals, maternity wards, nursing homes, and physician practices open. The bill also imposes damaging changes to federal student loan programs making it harder for students to pursue medical careers at a time of critical physician shortages. We urge the Senate to pursue more balanced solutions that expand the physician workforce and preserve Medicaid for our patients. "If these provider tax cuts are enacted, it will create significant gaps in State budgets, forcing states to raise taxes, or reduce benefits, coverage, and provider payments. These reductions will lead to even more crowding of emergency departments and as the uncompensated care burdens grow from patients losing coverage, many rural hospitals, nursing homes, and community physician practices will be forced to close to all patients," the letter says. There are three main provisions in H.R. 1 (as passed by the House of Representatives on May 22, 2025) that will drastically limit or eliminate existing provider taxes nationwide. These provisions below apply to all provider taxes, including hospitals, nursing homes, managed care organizations, and other provider categories. Moratorium on New or Increased Provider Taxes (SEC. 44132) – Under the provisions of H.R. 1, none of these taxes could be increased after the passage and enactment of the law nor can any new taxes be adopted by the state Legislatures (there are 19 categories of provider taxes). This provision would freeze taxes and not keep pace with increasing health care costs over time. It is also not equitable between states. Revising Payments for Certain State Directed Payments (SEC. 44133) – Once a provider tax is established, state Medicaid programs can fund supplemental or enhanced payments to providers using a variety of rate methodologies. Under H.R. 1, any future directed payments would be limited to the Medicare payment rate. Medicare physician payment rates are already 33% behind the costs to provide health care. These rates will not keep pace for public hospitals and physician specialists that care for the sickest patients nationwide. Requirements Regarding Waiver of Uniform Tax Requirement for Medicaid Provider Tax (SEC. 44134) – The language in H.R. 1 requires provider taxes in multiple states to uniformly tax hospitals, nursing homes, and managed care organizations within each category of provider tax. The uniformity requirement will be extremely difficult for most states to meet and therefore, it eliminates multiple provider taxes in many states. The HHS Secretary has discretion to allow for a transition period, which is not something upon which states can rely. "These provisions will destabilize state health systems, reduce access to care, and worsen physician shortages. Instead, we encourage you to protect Medicaid – a proven, cost-effective safety net that serves 80 million vulnerable Americans," the letter concluded. View original content to download multimedia: SOURCE California Medical Association; Physicians for Medicaid Sign in to access your portfolio
CBS News
9 hours ago
- CBS News
Fire at Shell cracker plant in Beaver County forces evacuation of multiple employees
A spokesperson for the Pennsylvania Department of Environmental Protection said a fire at the Shell cracker plant in Beaver County forced the evacuation of multiple employees and potentially released chemicals into the community. Anita White and Eli Matich worry about what could be in the air outside their home in Potter Township, just miles away from the plant. "It just feels scary, because you don't really know how it's impacting your health," White said. "When they built it, it was meant for job employment, help boost Beaver County. But instead, it's kind of been more negative than positive, it seems like," Matich said. It was just two days ago when smoke appeared to be billowing out of the facility, caused by what the state DEP calls a fire. It happened Wednesday afternoon at ethane cracking furnace #5. The DEP spokesperson said Shell reported that 15 employees were evacuated, and one person suffered a minor heat-related injury. KDKA obtained a photo showing a mangled furnace inside the complex. A Shell employee told KDKA that the damage is so bad it could result in them tearing it down and rebuilding. "It's definitely concerning," Matich said. The DEP spokesperson said it resulted in the "possible release of an unknown amount of 1,3-butadiene and benzene" in the air, and that the furnace "was not in production at the time." The agency added that an emergency response team member conducted an initial assessment at the plant and did not see any visible emissions or unintended releases of them due to a malfunction or other problem, along with any unpleasant smells. Also, their "air monitor did not register any emissions above zero, which means there weren't any air pollutants that lingered related [to] the fire." "We're always trying to eat healthy and be clean, but then we have these chemicals that are going into the air. So, it kind of feels like, all right, what's the point?" White said. Environmental experts describe what may have been released this week as cancer-causing chemicals. Since Shell started operating here in late 2022, it's faced several malfunctions and millions of dollars in fines. Shell did not disclose the potential release of chemicals in a Facebook post to the public, but a spokesperson told KDKA they informed the Nuclear Regulatory Commission, and "will submit the [investigation] findings, as required, to the Pennsylvania Emergency Management Agency (PEMA) and the Local Emergency Planning Commission (LEPC)." As for White and Matich, for the time being, they'll be staying where they are. "Until the housing market gets a bit better, so we can move a little farther away," White said. The DEP spokesperson said Shell is continuing to investigate and that the agency will ensure the company complies with environmental regulations for the health and safety of the community.
